Congenital Hypopituitarism Gene Panel
Test Overview
The Congenital Hypopituitarism Gene Panel is a comprehensive genetic test that identifies pathogenic variants associated with congenital hypopituitarism, a rare condition in which the pituitary gland fails to produce one or more essential hormones from birth. Early genetic diagnosis helps determine the underlying cause, guides treatment, and supports genetic counseling for affected families.
Why is this test performed?
- Diagnose inherited causes of congenital hypopituitarism.
- Identify genetic variants responsible for pituitary hormone deficiencies.
- Differentiate isolated hypopituitarism from syndromic disorders.
- Guide personalized treatment and long-term hormone replacement therapy.
- Assess recurrence risk in future pregnancies through genetic counseling.
Who should consider this test?
- Newborns or children with multiple pituitary hormone deficiencies.
- Individuals with unexplained growth failure or short stature.
- Patients with neonatal hypoglycemia or prolonged jaundice.
- Children with delayed puberty due to hormone deficiencies.
- Individuals with pituitary structural abnormalities on MRI.
- Families with a history of congenital hypopituitarism or related endocrine disorders.
Common Symptoms
- Poor growth or short stature
- Recurrent low blood sugar (hypoglycemia)
- Prolonged neonatal jaundice
- Feeding difficulties in infancy
- Delayed puberty
- Fatigue and weakness
- Hormonal deficiencies affecting thyroid, adrenal, or reproductive function
Genes Typically Included
The panel may include clinically relevant genes such as:
PROP1, POU1F1 (PIT1), HESX1, LHX3, LHX4, SOX2, SOX3, OTX2, GLI2, FGFR1, FGF8, PROKR2, IGSF1, GHRHR, RNPC3, and other validated genes associated with congenital hypopituitarism.
Sample Required
Method
- Next-Generation Sequencing (NGS)
- Deletion/Duplication analysis (when applicable)
Benefits
- Early and accurate genetic diagnosis
- Supports targeted hormone replacement therapy
- Reduces unnecessary diagnostic investigations
- Enables family screening and genetic counseling
- Assists in prognosis and long-term clinical management
Turnaround Time
Approximately 3–6 weeks (may vary depending on the laboratory protocol).
Note: A positive genetic result should always be interpreted alongside clinical findings, hormonal evaluation, and imaging studies by an endocrinologist or clinical geneticist.
